|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nucleoporin 88 expression in hepatitis B and C virus-related liver diseases显示文摘AIM: To investigate the expression of nucleoporin 88 (Nup88) in hepatitis B virus (HBV) and C virus (HCV)-related liver diseases. METHODS: We generated a new monoclonal Nup88 antibody to investigate the Nup88 protein expression by immunohistochemistry (IHC) in 294 paraffin-embedded liver specimens comprising all stages of hepatocellular carcinogenesis. In addition, in cell culture experiments HBV-positive (HepG2.2.15 and HB611) and HBV-negative (HepG2) hepatoma cell lines were tested for the Nup88 expression by Western-immunoblotting to test data obtained by IHC.RESULTS: Specific Nup88 expression was found in chronic HCV hepatitis and unspecific chronic hepatitis, whereas no or very weak Nup88 expression was detected in normal liver. The Nup88 expression was markedly reduced or missing in mild chronic HBV infection and inversely correlated with HBcAg expression. Irrespective of the HBV- or HCV-status, increasing Nup88 expression was observed in cirrhosis and dysplastic nodules, and Nup88 was highly expressed in hepatocellular carcinomas. The intensity of Nup88 expression significantly increased during carcinogenesis (P < 0.0001) and correlated with dedifferentiation (P < 0.0001). Interestingly, Nup88 protein expression was significantly downregulated in HBV-positive HepG2.2.15 (P < 0.002) and HB611 (P < 0.001) cell lines as compared to HBV-negative HepG2 cells. CONCLUSION: Based on our immunohistochemical data, HBV and HCV are unlikely to influence the expression of Nup88 in cirrhotic and neoplastic liver tissue, but point to an interaction of HBV with the nuclear pore in chronic hepatitis. The expression of Nup88 in nonneoplastic liver tissue might reflect enhanced metabolic activity of the liver tissue. Our data strongly indicate a dichotomous role for Nup88 in non-neoplastic and neoplastic conditions of the liver. | Martina Knoess Anna Kordelia Kurz Olga Goreva Nuran Bektas Kai Breuhahn Magarethe Odenthal Peter Schirmacher Hans Peter Dienes C Thomas Bock Hanswalter Zentgraf Axel zur Hausen | 2006 | World Journal of Gastroenterology2006，12，36： | 4 |
| 2 | The Globalization of Traditional Medicines: Perspectives Related to the European Union Regulatory Environment显示文摘In the Member States of the European Union (EU), a harmonized legislation on medicinal products has been enforced, which specifically defines herbal medicinal products and traditional herbal medicinal products. The scope was to create a regulatory environment that takes into account the particular characteristics of herbal medicinal products. The harmonization of standards is intended to harmonize assessment and facilitate access to the market in different Member States. The standards defined by the EU herbal monographs of the Committee on Herbal Medicinal Products (HMPC) and the quality requirements laid down in the European Pharmacopoeia represent an excellent model of multinational harmonization of the regulatory environment for herbal and traditional medicines. It has also been demonstrated that this framework is at least partially applicable for herbal and traditional medicines from traditional Chinese medicine (TCM) to gain access to the EU market. Moreover, the HMPC provides specific guidance documents and pilot projects on monographs on the safety and efficacy of Chinese herbal drugs. In the European Pharmacopoeia, the number of quality monographs of herbal drugs with an origin in TCM is continuously growing. These developments indicate that globalization of traditional medicines is an ongoing process. Communication and cooperation between regulators, the scientific community, and interested stakeholders will set the stage for the convergence of diverse regulatory environments. This will contribute to worldwide availability of traditional medicines based on appropriate standards. | Werner Knoess Jacqueline Wiesner | 2019 | Engineering2019，5，1： | 3 |
| 3 | Multi-modality imaging of uveal melanomas using combined PET/CT,high-resolution PET and MR imaging显示文摘 | Beyer T Pietrzyk U Knoess C | | 0，，02： | 1 |
| 4 | Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PET and MR imaging显示文摘 | Beyer T Pietrzyk U Knoess C | 2008 | Nuklearmedizin2008，47，2： | 1 |
| 5 | Regulation of herbal medicinal products in the EU: an up-to-date scientific review 显示文摘 | Chinou I Knoess W Calapai G | 2014 | Phytochem Rev2014，13，2： | 1 |
| 6 | Preparation and reactions of zinc and copperorganometallics bearing acidic hydrogens显示文摘 | KNOESS H P FURLONG M T ROZEMA M J | 1991 | J Org Chem1991，56，21： | 1 |
| 7 | Overview of Herbal Regulatory Environment in the EU显示文摘Ladies and gentlemen, it is a great pleasure for me to be here to thank DIA and also CPA for inviting me and having this very interesting workshop with many people around the world, who are especially from EU and China, and are experts on herbal and traditional medicines. And all I am going to do is just using 30 minutes to give you an overview on the regulatory framework existing in the European Union. | Werner Knoess | 2019 | World Journal of Integrated Traditional and Western Medicine2019，5，3： | 0 |
| 8 | Panel Discussion显示文摘IMPACT OF BREXIT ON CHINESE COMPANIES' ACCESS TO THE EUROPEAN MARKET Q: We have a product, which was approved in UK in 2017. Now we want to expand the market to the Europe. Do you have any suggestions about which country is easier to accept traditional Chinese medicine? | Joseph Scheeren Werner Knoess Diane Wilkinson Zhang Junhua Bernd Roether Zhang Shunnan Karin Schleisiek | 2019 | World Journal of Integrated Traditional and Western Medicine2019，5，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员